|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.730 USD | +2.37% |
|
+15.33% | -28.22% |
| 08-05 | Acrivon Therapeutics Advances Acr-2316 into Randomized Dose Expansion in Ongoing Phase 1/2 Study | CI |
| 05-15 | Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) | RE |
| Market Cap | 74.05M 64.05M 59.81M 54.87M 103M 7.05B 105M 702M 275M 3.53B 278M 272M 11.68B | P/E 2026 * |
-0.84x | P/E 2027 * | -0.89x |
|---|---|---|---|---|---|
| Enterprise Value | 74.05M 64.05M 59.81M 54.87M 103M 7.05B 105M 702M 275M 3.53B 278M 272M 11.68B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 509x |
| Free-Float |
84.57% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Acrivon Therapeutics, Inc.
| 1 day | +2.37% | ||
| 1 week | +15.33% | ||
| Current month | +15.33% | ||
| 1 month | -15.20% | ||
| 3 months | -12.63% | ||
| 6 months | +3.59% | ||
| Current year | -28.22% |
| 1 week | 1.48 |  | 1.76 |
| 1 month | 1.41 | | 2.16 |
| Current year | 1.27 | | 3.56 |
| 1 year | 1.2 | | 3.56 |
| 3 years | 1.05 | | 12.89 |
| 5 years | 1.05 | | 25.47 |
| 10 years | 1.05 | | 25.47 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kristina Masson
COO | Chief Operating Officer | 46 | 2018-02-28 |
| Chief Executive Officer | 64 | 2018-03-31 | |
Adam Levy
DFI | Director of Finance/CFO | 60 | 2025-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 64 | 2018-03-31 | |
Kristina Masson
BRD | Director/Board Member | 46 | 2018-02-28 |
Sharon Shacham
BRD | Director/Board Member | 55 | 2020-09-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/4/26 | Sell | Chief Financial Officer | -1,142 | 0.0027% | ||
| 7/21/26 | Sell | General Counsel | -573 | 0.0013% | ||
| 6/17/26 | Free | Director | 20,275 | 0.0474% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.37% | +15.33% | +39.52% | -85.41% | 74.05M | |
| +0.99% | +1.78% | +5.07% | +16.49% | 49.47B | |
| +3.71% | +9.40% | +486.14% | +579.98% | 43.97B | |
| +5.60% | +10.21% | +20.85% | +81.78% | 39.6B | |
| +2.70% | +1.57% | +32.71% | +9.07% | 39.29B | |
| +2.21% | +6.75% | +20.20% | +54.40% | 32.43B | |
| +2.23% | +4.71% | - | - | 16.84B | |
| +0.97% | +2.35% | +35.99% | +124.45% | 16.49B | |
| -0.11% | +2.41% | +5.03% | +20.47% | 14.01B | |
| +0.75% | +15.04% | +79.84% | +29.70% | 12.77B | |
| Average | +2.14% | +7.22% | +80.59% | +92.33% | 26.49B | |
| Weighted average by Cap. | +2.54% | +6.10% | +105.12% | +138.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 146K 126K 118K 108K 203K 13.85M 206K 1.38M 541K 6.94M 546K 534K 22.95M |
| Net income | -84.75M -73.31M -68.46M -62.8M -118M -8.07B -120M -803M -315M -4.04B -318M -311M -13.36B | -109M -94.53M -88.28M -80.98M -152M -10.4B -155M -1.04B -407M -5.21B -410M -401M -17.23B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-07 | US$1.730 | +2.37% | 302,253 |
| 26-08-06 | US$1.690 | +3.05% | 316,165 |
| 26-08-05 | US$1.640 | +5.13% | 318,805 |
| 26-08-04 | US$1.560 | 0.00% | 184,297 |
| 26-08-03 | US$1.560 | +4.00% | 242,025 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ACRV Stock
Select your edition
All financial news and data tailored to specific country editions
